Open Access Articles- Top Results for Talipexole


Systematic (IUPAC) name
Clinical data
AHFS/ International Drug Names
  • (Prescription only)
36085-73-1 7pxN
PubChem CID 5374
ChemSpider 5181 7pxN
UNII 7AM2J46Z1Y 7pxN
ChEMBL CHEMBL1289023 7pxN
Chemical data
Formula C10H15N3S
209.31 g/mol
 14pxN (what is this?)  (verify)

Talipexole (B-HT920, Domnin) is a dopamine agonist that is marketed as a treatment for Parkinson's Disease in Japan by Boehringer Ingelheim; it was introduced in 1996.[1] As of December 2014 it was not approved for marketing in the US nor in Europe.[2]

Talipexole is a D2 dopamine receptor agonist and interacts both pre- and post-synaptic receptors. It also is an α2-adrenergic agonist.[3]

The main side effects are drowsiness, dizziness, hallucinations and minor gastrointestinal complaints.[3] In 2008 the Japanese Ministry of Health, Labour, and Welfare mandated that Boehringer add a warning to the label concerning the risk of sudden onset of sleep.[4]:15


  1. ^ PharmaLetter 22 July 1996 First Launch In Japan For Talipexole
  2. ^ EvaluatePharma Database. Page accessed 9 December 2014
  3. ^ a b Benkert O, et al. Dopamine agonists in schizophrenia: a review. Eur Neuropsychopharmacol. 1995;5 Suppl:43-53. PMID 8775758
  4. ^ Japanese Ministry of Health, Labour and Welfare March 2008 Pharmaceuticals and Medical Devices Safety Information No. 245

Lua error in package.lua at line 80: module 'Module:Buffer' not found.